InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Written by Kirsten Ruehl on 30th August 2023. Posted in Client News.

• Previous
• Next